Dr. Wasik Ashraf, an Orthopaedic Surgeon specializing in Sports Medicine, discusses trends and innovation in Orthobiologics and Regenerative Medicine in an interview with SmartTRAK.

In this wide-ranging interview, Dr. Ashraf gives his view of CMS' FY21 OPPS-ASC Final Rulemaking, and discusses emerging trends and innovation in OrthoBiologics and Regenerative Medicine. As a Board-certified and fellowship-trained physician specializing in sports medicine, joint preservation and cartilage restoration, Dr. Ashraf offers his unique view and perspective on some of the newest technologies he is using, as well as those to look out for in the coming years. 

To listen to the interview, recorded live via Uberconference, click on the following video (41:37 min). A transcript of the interview is also available below.

As states begin to loosen restrictions and we try and put COVID-19 in the rear view mirror, in the words of Bill Gates, "it's going to be a while before we can get back to normal" and companies are going to have to find creative ways to stay connected and engaged while moving forward and getting work done.

The following is a small sampling of Regenerative Medicine segment updates from the past week that were compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present news, analysis, studies, trial results, patents and financial data that are most relevant to our subscribers.

The GID Group – Prepping to revolutionize Regenerative Medicine with an innovative modular tissue processing platform

In December, at IFATS 2019, William “Bill” Cimino, PhD, CEO of The GID Group (GID) sat down with SmartTRAK to discuss the Company’s novel modular tissue processing platform, which reduces an entire GMP cell-processing facility to a single disposable device, enabling physicians to extract and process adipose tissue in real time for use in a wide range of applications.

GID is a privately held, clinical stage cellular medicine company currently working on developing a tissue processing platform, the GID SVF-2 device, that enables cell-based treatments.

To find out more about the GID Group, its revolutionary technology and product candidate, click on the following video to listen to SmarTRAK’s interview with Bill Cimino, recorded live at the IFATS Annual Meeting held in Marseille, France December 3-7, 2019. A transcript of the interview is also provided below.

Location: Northeast region of US (NY, NJ, MA, PA)

Full-time Position

Position:

BioMedGPS, a leading strategic advisory and healthcare analytics firm serving the life sciences industry, is seeking a Director of Enterprise Sales with extensive healthcare B2B experience for its SmartTRAK Business Intelligence platform and related products. Applicant must reside in the Northeastern region of the USA for easy access to major accounts.

SmartTRAK is the first business intelligence portal that provides real time data, analytics and curated content by a team of industry experts to help medical device executives make more informed strategic decisions. SmartTRAK is utilized by leading medical device companies within the orthopedic, wound care, regenerative medicine and neuro therapeutic areas. The Director of Sales will be responsible for selling SmartTRAK’s suite of business intelligence solutions to C- suite and other senior level executives, as well as building long term strategic programs and relationships at all levels of the enterprise.

The US Surgical Matrices Market continued its modest growth in Q219, with growth in breast matrices continuing to outpace hernia matrices.

SmartTRAK reports that the US Surgical Matrices market, comprised of matrices used for Breast Reconstruction and Hernia Repair, experienced single digit growth in Q219 according to SmartTRAK estimates. The fast-growing Breast Reconstruction segment slowed to +4.6% YoY during the quarter, while the US Hernia Repair market ticked up slightly to +2.9% YoY.

Among the many topics covered in the Q219 US Surgical Matrices Market Recap* are:

OrthogenRx CEO & Founder Michael Daley talks about the Company’s new 3-injection HA product, TriVisc and what will come next.

Michael Daley, CEO & Founder of OrthogenRx, a US medical device company focused on treatments for musculoskeletal conditions, talked about TriVisc, the Company’s new 3-injection hyaluronic acid (HA) product for knee osteoarthritis, as well as the future at OrthogenRx, in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting held March 12-14, 2019 in Las Vegas, NV.

What is the rational for OrthogenRx to bring TriVisc now to a very crowded 3-injection HA segment?

To have a presence in the entire US HA market, OrthogenRx aims to provide...

Frederique Buntoum (aka Freddy), SmartTRAK's Senior Analyst, Regenerative Medicine, overseeing the Cell Processing, Amniotic Tissue and Joint Fluid modules, will be representing SmartTRAK at TOBI 2019, the Tenth Annual PRP & Regenerative Medicine Symposium in Chicago, IL, June 6-8. 

You can view Freddy's intro video below...

Frederique Buntoum (aka Freddy) has joined BioMedGPS as Senior Analyst, Regenerative Medicine, overseeing the Cell Processing, Amniotic Tissue and Joint Fluid modules. Formerly Senior Manager of Market Insights at Bioventus, Freddy has broad experience in sales, marketing and competitive intelligence. Her passion for market research and uncovering the “why” behind industry developments complements SmartTRAK’s team of domain experts and her thoughtful and keen insights and out-of-the-box perspective on market happenings make her a great addition to the SmartTRAK analyst team.

In addition to her role as an analyst, Freddy will also be assisting with consulting projects and product development initiatives – two key areas that will contribute to BioMedGPS growth in 2019.

Freddy will be representing SmartTRAK at the upcoming AAOS meeting. Please Contact us if you would like to set up a time to meet.

The US Surgical Matrices Market continued to advance in Q318, up +10.3% YoY, fueled by continued rapid adoption of allograft breast matrices and the resurgence of synthetic hernia matrices.

According to BioMedGPS’ SmartTRAK Financial Dashboard, in Q318, the US Surgical Matrices Market grew +10.3% YoY. The allograft breast matrices and biosynthetic hernia matrices segments outpaced overall market growth, as both posted...

Among the many interesting topics covered in the Q318 US Surgical Matrices Market Recap are: